Article Text

Download PDFPDF
Letter
Geographic variation in molecular subtype for gastric adenocarcinoma
  1. Ping Liao1,
  2. Feifei Jia1,2,
  3. Jamie K Teer3,
  4. Todd C Knepper2,
  5. Hong-Hao Zhou1,
  6. Yi-Jing He1,2,
  7. Howard L McLeod1,2
  1. 1 Hunan Key Laboratory of Pharmacogenetics, Department of Clinical Pharmacology, Institute of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China
  2. 2 Moffitt Cancer Center, DeBartolo Family Personalized Medicine Institute, Tampa, Florida, USA
  3. 3 Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, USA
  1. Correspondence to Dr Yi-Jing He, Department of Clinical Pharmacology, XiangYa Hospital, Central South University, Changsha, Hunan, China; yijing.he{at}moffitt.org and Prof Howard L McLeod, Moffitt Cancer Center, DeBartolo Family Personalized Medicine Institute, Tampa, FL 33612, USA; Howard.McLeod{at}moffitt.org

Statistics from Altmetric.com

The presence of distinct molecular subgroups of gastric cancer (GC) has been recently highlighted in Gut.1 2 However, there has been little focus on the geographic distribution of molecular subgroups. Differences in GC molecular subtypes were assessed using data from The Cancer Genome Atlas (TCGA). Razvan et al established four clinically relevant molecular subtypes, which are MSS (microsatellite stable)/TP53−, MSS/TP53+, MSI (microsatellite instability) and MSS/EMT (epithelial–mesenchymal transition), further delineating GC.3 The clinical significance has been evaluated in a recent study using the TCGA proposed comprehensive molecular classification of patients with GC into four subtypes: Epstein-Barr virus (EBV), chromosomal instability (CIN), MSI and genomically stable (GS). Sohn et al reported that CIN and MSI subtypes had better overall survival than GS, but worse than EBV subtypes.4 Identification of molecular subtypes of GC may offer improved ways to monitor the progression, and predict prognosis …

View Full Text

Footnotes

  • Contributors PL is the guarantor of the study, performed the research and wrote the paper. FJ performed the research and wrote the paper. TCK is the clinical study coordinator. HHZ collected the data. JKT analysed the data. HLM and YJH designed the study.

  • Funding This work was supported by the National Natural Science Foundation of China (Grant No 81673517 and No 81773821), the National Key Research and Development Program (No 2016YFC0905000), the DeBartolo Family Personalized Medicine Institute, the State of Florida Cancer Research Endowed Chair and the Collins Charitable Foundation. This work is dedicated to Don McLeod and Dr Todd Morton, both whom lost their lives to gastric cancer.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.